p.95 抽出テキスト
481. Chow CK, Thakkar J, Bennett A, Hillis G, Burke M, Usherwood T, et al. Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebocontrolled, crossover, randomised trial and systematic review. Lancet 2017;389: 1035–42. https://doi.org/10.1016/s0140-6736(17)30260-x 482. Chow CK, Atkins ER, Hillis GS, Nelson MR, Reid CM, Schlaich MP, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet 2021; 398:1043–52. https://doi.org/10.1016/s0140-6736(21)01922-x 483. Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed low-dose triple combination antihypertensive medication vs usual care for blood pressure control in patients with mild to moderate hypertension in Sri Lanka: a randomized clinical trial. JAMA 2018;320:566–79. https://doi.org/10.1001/jama.2018.10359 484. MacDonald TM, Williams B, Webb DJ, Morant S, Caulfield M, Cruickshank JK, et al. Combination therapy is superior to sequential monotherapy for the initial treatment of hypertension: a double-blind randomized controlled trial. J Am Heart Assoc 2017;6: e006986. https://doi.org/10.1161/jaha.117.006986 485. Salam A, Kanukula R, Atkins E, Wang X, Islam S, Kishore SP, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 2019;37:1768–74. https://doi.org/10.1097/hjh.0000000000002096 486. Zhang ZY, Yu YL, Asayama K, Hansen TW, Maestre GE, Staessen JA. Starting antihypertensive drug treatment with combination therapy: controversies in hypertension— con side of the argument. Hypertension 2021;77:788–98. https://doi.org/10.1161/ hypertensionaha.120.12858 487. Kahan T. Low-dose combination of blood pressure-lowering medicines. Lancet 2021; 398:1022–3. https://doi.org/10.1016/s0140-6736(21)01964-4 488. Rea F, Corrao G, Merlino L, Mancia G. Initial antihypertensive treatment strategies and therapeutic inertia. Hypertension 2018;72:846–53. https://doi.org/10.1161/ hypertensionaha.118.11308 489. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension 2012;59:1124–31. https://doi.org/10.1161/hypertensionaha.112.194167 490. Sundström J, Lind L, Nowrouzi S, Hagström E, Held C, Lytsy P, et al. Heterogeneity in blood pressure response to 4 antihypertensive drugs: a randomized clinical trial. JAMA 2023;329:1160–9. https://doi.org/10.1001/jama.2023.3322 491. Tsioufis K, Kreutz R, Sykara G, van Vugt J, Hassan T. Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. J Hypertens 2020;38:1016–28. https://doi.org/10.1097/ hjh.0000000000002381 492. Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus freeequivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension 2021;77:692–705. https://doi.org/10.1161/hypertensionaha.120.15781 493. Egan BM, Kjeldsen SE, Narkiewicz K, Kreutz R, Burnier M. Single-pill combinations, hypertension control and clinical outcomes: potential, pitfalls and solutions. Blood Press 2022;31:164–8. https://doi.org/10.1080/08037051.2022.2095254 494. Yusuf S, Joseph P, Dans A, Gao P, Teo K, Xavier D, et al. Polypill with or without aspirin in persons without cardiovascular disease. N Engl J Med 2021;384:216–28. https://doi. org/10.1056/NEJMoa2028220 495. Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet 2019;394:672–83. https://doi.org/10.1016/s0140-6736(19)31791-x 496. Joseph P, Roshandel G, Gao P, Pais P, Lonn E, Xavier D, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet 2021;398:1133–46. https://doi.org/10. 1016/s0140-6736(21)01827-4 497. van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad J-J, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012;33:2088–97. https://doi.org/10. 1093/eurheartj/ehs075 498. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367: 2204–13. https://doi.org/10.1056/NEJMoa1208799 499. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892–903. https://doi.org/10.1056/NEJMoa1303154 500. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–59. https://doi.org/10.1056/NEJMoa0801317 501. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55: 399–407. https://doi.org/10.1161/hypertensionaha.109.139816 502. Gnanenthiran SR, Wang N, Di Tanna GL, Salam A, Webster R, de Silva HA, et al. Association of low-dose triple combination therapy vs usual care with time at target blood pressure: a secondary analysis of the TRIUMPH randomized clinical trial. JAMA Cardiol 2022;7:645–50. https://doi.org/10.1001/jamacardio.2022.0471 503. Tam TS, Wu MH, Masson SC, Tsang MP, Stabler SN, Kinkade A, et al. Eplerenone for hypertension. Cochrane Database Syst Rev 2017;2:CD008996. https://doi.org/10.1002/ 14651858.CD008996.pub2 504. Pedersen ME, Cockcroft JR. The vasodilatory beta-blockers. Curr Hypertens Rep 2007; 9:269–77. https://doi.org/10.1007/s11906-007-0050-2 505. Sica DA. Minoxidil: an underused vasodilator for resistant or severe hypertension. J Clin Hypertens (Greenwich) 2004;6:283–7. https://doi.org/10.1111/j.1524-6175.2004.03585.x 506. Muñoz D, Uzoije P, Reynolds C, Miller R, Walkley D, Pappalardo S, et al. Polypill for cardiovascular disease prevention in an underserved population. N Engl J Med 2019; 381:1114–23. https://doi.org/10.1056/NEJMoa1815359 507. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, et al. Polypill strategy in secondary cardiovascular prevention. N Engl J Med 2022;387: 967–77. https://doi.org/10.1056/NEJMoa2208275 508. González-Juanatey JR, Cordero A, Castellano JM, Masana L, Dalmau R, Ruiz E, et al. The CNIC-polypill reduces recurrent major cardiovascular events in real-life secondary prevention patients in Spain: the NEPTUNO study. Int J Cardiol 2022;361:116–23. https://doi.org/10.1016/j.ijcard.2022.05.015 509. Jowett S, Barton P, Roalfe A, Fletcher K, Hobbs FDR, McManus RJ, et al. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease. PLoS One 2017; 12:e0182625. https://doi.org/10.1371/journal.pone.0182625 510. McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet 2010;376:163–72. https://doi.org/10.1016/s0140-6736(10)60964-6 511. Clark CE, Smith LF, Taylor RS, Campbell JL. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. BMJ 2010;341:c3995. https://doi.org/10.1136/bmj.c3995 512. Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet 2022;400:1417–25. https://doi.org/ 10.1016/s0140-6736(22)01786-x 513. Conn VS, Ruppar TM, Chase JA, Enriquez M, Cooper PS. Interventions to improve medication adherence in hypertensive patients: systematic review and meta-analysis. Curr Hypertens Rep 2015;17:94. https://doi.org/10.1007/s11906-015-0606-5 514. Corrao G, Parodi A, Zambon A, Heiman F, Filippi A, Cricelli C, et al. Reduced discontinuation of antihypertensive treatment by two-drug combination as first step. Evidence from daily life practice. J Hypertens 2010;28:1584–90. https://doi.org/10. 1097/HJH.0b013e328339f9fa 515. Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (resistant hypertension optimal treatment). Hypertension 2018;71:681–90. https://doi.org/10.1161/hypertensionaha.117.10662 516. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol 2018;6:464–75. https://doi.org/10.1016/s2213-8587(18) 30071-8 517. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547–53. https://doi.org/10.1016/s0140-6736(08)61236-2 518. Jones DW, Whelton PK, Allen N, Clark D III, Gidding SS, Muntner P, et al. Management of stage 1 hypertension in adults with a low 10-year risk for cardiovascular disease: filling a guidance gap: a scientific statement from the American Heart Association. Hypertension 2021;77:e58–67. https://doi.org/10.1161/hyp.0000000000000195 519. Ali DH, Kiliç B, Hart HE, Bots ML, Biermans MCJ, Spiering W, et al. Therapeutic inertia in the management of hypertension in primary care. J Hypertens 2021;39:1238–45. https://doi.org/10.1097/hjh.0000000000002783 520. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003;289:2083–93. https://doi.org/10.1001/jama. 289.16.2083 521. Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 2005;294:2455–64. https://doi.org/10. 1001/jama.294.19.2455 522. Thomopoulos C, Parati G, Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens 2017;35: 2150–60. https://doi.org/10.1097/hjh.0000000000001547 523. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease Downloaded from academic.oup.com/eurheartj/article/45/38/3912/7741010 by guest on 07 October 2026